GSK wins Hibsago approval: Jefferies keeps GBp 2,500 target for GSK stock

Published on 10/22/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hibsago posted a 19 percent functional cure rate on October 21, 2026. GSK stock costs EUR 22.35, 0.22 percent above the Xetra close.

Pipeline approvals and analyst targets

Hibsago achieved a 19 percent functional cure rate in phase three trials on October 21, 2026.
GSK reported GBP 8.41 billion in second-quarter revenue for 2026.
GSK stock trades at EUR 22.35 at 9:46 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.22 percent above the Xetra close of October 21, 2026.
Jefferies maintained a GBp 2,500 target on October 21, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) said Hibsago won US approval for chronic hepatitis B after phase three data showed a 19 percent functional cure rate on October 21, 2026, according to Finanznachrichten. Jefferies also maintained a Buy rating and a GBp 2,500 price target in a report covered by MarketBeat.

Three events shape the pipeline

GSK's recent sequence of events shows why the hepatitis B approval matters. On July 28, 2026, the company reported second-quarter revenue of GBP 8.41 billion, compared with GBP 7.99 billion a year earlier, while net profit was GBP 435.00 million versus GBP 1.44 billion, according to Business Insider.

On October 19, 2026, GSK disclosed that Jemperli had secured US approval for locally advanced rectal cancer. The AZUR-1 study showed a 68 percent sustained complete response rate at 12 months among investigator-assessed patients, according to GSK.

On October 21, 2026, the Hibsago approval added a second late-stage regulatory catalyst. The reported 19 percent functional cure rate compares with less than 1 percent for standard care alone after one year, although the treatment remains tied to defined patient criteria and follow-up.

What does the target imply?

Jefferies' GBp 2,500 target stands above the GBp 1,868 price cited in its report, while the wider analyst average was GBp 2,064.38. The target and the current euro quotation use different currencies, so they are not combined into one return calculation.

Next date for the stock

GSK's next reported results are scheduled for October 28, 2026, according to the company's investor communications. That date will put the Hibsago approval, Jemperli progress and second-quarter revenue trend into the same reporting frame.

Price remains near EUR 22

The stock's market backdrop is steady rather than directional. It was trading at EUR 22.35 at Lang & Schwarz on October 22, 2026 at 9:46 a.m. CEST, 0.22 percent above the Xetra close of October 21, 2026 at EUR 22.30.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.